Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
Global In Vitro Diagnostics (IVD) Quality Control market was valued at USD 0.57 billion in 2024. The market is projected to grow from USD 0.59 billion in 2025 to USD 0.72 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.4% during the forecast period.
In Vitro Diagnostics Quality Controls are critical materials used to monitor the accuracy and precision of diagnostic tests performed on samples like blood or tissue outside the human body. These controls are essential for ensuring the reliability of test results across various platforms, including clinical chemistry, immunochemistry, hematology, molecular diagnostics, and coagulation. They act as a benchmark for performance, helping laboratories comply with stringent regulatory standards and maintain accreditation.
The market growth is steady, driven by the increasing volume of diagnostic testing globally, which is itself fueled by the rising prevalence of chronic and infectious diseases. The high demand for reliable diagnostic results, especially post-pandemic, underscores the importance of robust quality control systems. Furthermore, technological advancements in diagnostic instruments necessitate more sophisticated control materials. Key players like Bio-Rad Laboratories, Inc. and Siemens Healthineers AG dominate the market. For instance, Bio-Rad's expansive portfolio, including its Bio-Rad Unity Interlaboratory Program, exemplifies the innovative solutions driving market consistency and growth.
Rising Demand for Diagnostic Testing
The global expansion of healthcare infrastructure and increasing access to diagnostic services are primary factors driving the IVD quality control market. The growing prevalence of chronic diseases, such as diabetes and cardiovascular conditions, necessitates frequent and accurate diagnostic testing, which relies on effective quality control to ensure patient safety. Furthermore, the rising adoption of automated immunoassay analyzers and molecular diagnostic techniques in clinical laboratories has heightened the need for robust quality control solutions to maintain instrument precision and test reliability.
Implementation of Stringent Regulatory Frameworks
Governments and international health bodies are enforcing more rigorous quality standards for diagnostic laboratories. Regulations such as the Clinical Laboratory Improvement Amendments (CLIA) in the United States and the In Vitro Diagnostic Regulation (IVDR) in Europe mandate the use of quality control materials to validate test performance. This regulatory pressure compels laboratories to invest in comprehensive QC programs, driving consistent market growth. The focus on achieving and maintaining accreditation from bodies like the College of American Pathologists (CAP) further underscores this requirement.
Adoption of third-party quality control materials is increasing as laboratories seek unbiased, multi-vendor performance assessment for their analytical systems.
The trend towards personalized medicine and the development of novel biomarkers for targeted therapies are creating a demand for specialized quality controls. As tests become more complex, QC materials must evolve to accurately mimic patient samples and ensure the validity of results for critical treatment decisions. This technological advancement, coupled with the rising number of accredited laboratories worldwide, provides a strong foundation for sustained market expansion.
MARKET CHALLENGES
High Cost and Budgetary Constraints
The procurement and implementation of a complete IVD quality control system, including instruments, software, and consumables, represent a significant financial investment for diagnostic laboratories, especially in cost-sensitive markets and developing regions. The recurring expense of quality control materials adds to the operational budget, which can be a barrier for smaller labs or those with limited funding. Budgetary pressures in public healthcare systems can delay or limit the adoption of advanced QC solutions.
Other Challenges
Lack of Skilled Professionals
There is a global shortage of laboratory personnel with specialized training in quality management and data interpretation for advanced IVD systems. This skills gap can lead to improper implementation of QC protocols and misinterpretation of control data, ultimately compromising the effectiveness of the entire quality assurance program and potentially affecting patient diagnoses.
Logistical and Stability Issues
Quality control materials, particularly those for esoteric or unstable analytes, require stringent storage conditions (e.g., cold chain) and have limited shelf lives. Managing inventory to prevent wastage while ensuring the constant availability of controls for a wide test menu presents a significant logistical challenge for laboratories, impacting both cost and operational efficiency.
Preference for Instrument-Specific Controls
A notable restraint for third-party QC manufacturers is the continued preference of many laboratories for instrument-specific or manufacturer-defined quality controls provided by IVD instrument vendors. These controls are often optimized for specific reagent lots and systems, creating a perception of higher reliability. This preference can limit the market share for independent QC providers, despite the advantages of multi-vendor comparability that third-party controls offer.
Technological Limitations for Novel Assays
The rapid pace of innovation in IVD, particularly in areas like next-generation sequencing and digital pathology, presents a challenge for QC manufacturers. Developing control materials that accurately reflect the complex matrices and analytes of these cutting-edge tests is technically difficult and time-consuming. This lag in QC product development can temporarily restrain the adoption of new diagnostic technologies in routine clinical practice.
Expansion in Emerging Economies
Emerging markets in Asia-Pacific, Latin America, and the Middle East present significant growth opportunities. Rising healthcare expenditure, increasing privatization of healthcare services, and government initiatives to improve the quality of diagnostic infrastructure are driving the establishment of new clinical laboratories. This expansion creates a substantial, underserved demand for reliable and affordable IVD quality control products and services.
Integration of Data Management Solutions
The growing volume of QC data generated by modern laboratories creates an opportunity for integrated data management and analytics solutions. Cloud-based QC data management platforms that offer real-time monitoring, trend analysis, automated reporting, and peer-group comparison are increasingly sought after. These solutions help labs improve efficiency, ensure compliance, and make data-driven decisions, representing a high-value segment for market players.
Development of Customized and Multiplexed Controls
There is a growing demand for customized quality control materials tailored to specific laboratory test menus and patient populations. Additionally, the shift towards multiplexed testing (running multiple tests on a single sample) requires QC materials that can simultaneously control for several analytes. Developing these sophisticated, value-added products allows companies to cater to specialized market segments and command premium pricing.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Product controls constitute the fundamental segment, providing the physical or digital materials essential for daily quality assurance. The demand for these controls is deeply entrenched in the operational workflows of diagnostic facilities, as they are indispensable for instrument calibration and ensuring the reliability of every test result. While services are growing in strategic importance, particularly for complex laboratory management, the ongoing, routine necessity for high-quality control products ensures their continued preeminence in the market landscape, driven by continuous testing volumes and the introduction of new diagnostic assays. |
| By Application |
|
Clinical Laboratories represent the core application segment due to their high-volume, routine diagnostic testing environment where accuracy is non-negotiable. These facilities conduct a vast array of tests daily, making robust quality control systems critical for regulatory compliance and patient safety. While large hospitals are also significant consumers, the specialized, high-throughput nature of dedicated clinical laboratories creates a more concentrated and consistent demand for sophisticated quality control solutions. The segment's leadership is reinforced by stringent accreditation standards that govern laboratory operations worldwide, ensuring continuous investment in quality assurance. |
| By End User |
|
Clinical Laboratories are the primary end-users, as they are the direct implementers of quality control protocols in patient testing. Their persistent need to verify the performance of their diagnostic equipment and reagents creates a stable and recurring revenue stream for QC providers. Diagnostic instrument manufacturers are also crucial end-users, utilizing controls for research, development, and the pre-market validation of new devices. The demand from this segment is driven by innovation cycles and the launch of new, more complex diagnostic platforms that require accompanying specialized control materials to ensure they function as intended. |
| By Technology |
|
Clinical Chemistry remains the dominant technological segment, underpinned by its status as the backbone of routine diagnostic testing in laboratories globally. The sheer volume of tests performed for metabolic panels, electrolytes, and liver and kidney functions necessitates extensive and reliable quality control. However, the segment for Molecular Diagnostics is exhibiting the most dynamic growth, fueled by the expanding adoption of PCR and genomic testing for infectious diseases, oncology, and genetic disorders. The complexity and critical nature of these tests demand highly specific and sensitive controls, creating a high-value niche within the market. |
| By Form |
|
Liquid/Ready-to-Use controls are the leading segment by form, prized for their convenience, stability, and reduction of preparation errors in busy laboratory settings. Their ease of use directly supports workflow efficiency and minimizes the potential for variability introduced during manual reconstitution. Although lyophilized powders offer benefits in terms of shelf life and transportation, the strong market preference leans towards the operational simplicity and time-saving advantages of liquid controls. This trend is particularly pronounced in high-volume laboratories where streamlining processes is a key priority for maintaining productivity and ensuring consistent test turnaround times. |
Dominated by Established Giants with a Strong Presence of Specialized Niche Players
The global In Vitro Diagnostics Quality Control market is characterized by a high degree of consolidation, with a few multinational corporations commanding significant market share. Leading this group is Bio-Rad Laboratories, a dominant force renowned for its comprehensive portfolio of third-party quality controls that span clinical chemistry, immunoassay, hematology, molecular diagnostics, and blood gas. Roche Diagnostics and Siemens Healthineers are also major players, leveraging their extensive global reach and integrated IVD systems to offer synergistic quality control solutions. Thermo Fisher Scientific and Abbott Laboratories further solidify the top tier, providing a wide array of controls and calibrators critical for ensuring the accuracy and reliability of diagnostic tests across laboratories worldwide. This concentration is driven by the need for stringent regulatory compliance, extensive R&D investments, and established distribution networks.
Beyond the market leaders, a segment of specialized and regional players contributes to the competitive dynamics by catering to specific niches. Companies like Randox Laboratories have carved out a strong position with their extensive test menu and custom quality control services. Serocare Life Sciences (now part of LGC Standards) is a key participant in the molecular diagnostics QC segment, providing critical materials for assays. Other notable companies such as Sysmex, Ortho Clinical Diagnostics, and Helena Laboratories focus on specific diagnostic segments like hematology and immunology. Additionally, firms like Quantimetrix and Sun Diagnostics address specific laboratory needs with specialized control products, ensuring a diverse and competitive market landscape that fosters innovation and addresses the varied requirements of clinical laboratories.
List of Key In Vitro Diagnostics Quality Control Companies ProfiledAbbott Laboratories
Helena Laboratories
Ortho Clinical Diagnostics
Serocare Life Sciences (LGC Standards)
Sun Diagnostics
Thermo Fisher Scientific
Sysmex Corporation
Quantimetrix
The global In Vitro Diagnostics (IVD) Quality Control market is on a path of consistent expansion, valued at $573 million in 2024 and projected to reach $718 million by 2032, growing at a compound annual growth rate (CAGR) of 3.4%. This growth is fundamentally driven by the critical role of quality controls in ensuring diagnostic accuracy, which is paramount for effective patient care and treatment decisions. The increasing reliance on diagnostic testing across healthcare settings underscores the necessity for robust quality assurance processes to maintain the integrity and reliability of test results.
Other TrendsExpansion of the Broader Pharmaceutical Market
The growth of the IVD Quality Control market is interlinked with the dynamics of the global pharmaceutical market, which was valued at $1475 billion in 2022 and is growing at a CAGR of 5%. Factors such as the rising prevalence of chronic diseases, technological advancements, and increased R&D funding are propelling both the chemical and biological drug segments. As new pharmaceuticals are developed, the demand for accurate diagnostic tests to monitor treatment efficacy and patient health increases, thereby driving the need for reliable quality controls in diagnostic laboratories.
Segmentation and Application Trends
The market is segmented by type into products and services, and by application into hospitals, clinical laboratories, research and academic institutes, and others. Clinical laboratories represent a dominant application segment due to the high volume of diagnostic tests processed. The trend toward consolidation of laboratory services and the expansion of point-of-care testing are influencing the demand for specialized quality control solutions tailored to these environments.
Regulatory Scrutiny and Technological IntegrationThe industry operates under stringent regulatory frameworks that mandate the use of quality controls to ensure test validity. This regulatory pressure is a significant driver for market growth but also presents a challenge in terms of compliance costs. A key trend is the integration of advanced technologies, such as data management software, with quality control products to streamline compliance, track performance over time, and facilitate corrective actions. Leading companies are focusing on developing multi-analyte controls and third-party controls that offer greater independence and reliability compared to instrument-specific controls provided by manufacturers.
Regional Analysis: In Vitro Diagnostics Quality Control MarketEurope
Europe represents a highly mature and regulated market for IVD quality controls, characterized by the implementation of the In Vitro Diagnostic Regulation (IVDR). This new regulation places greater emphasis on performance evaluation and post-market surveillance, significantly increasing the need for reliable quality control processes. Countries like Germany, the UK, and France have well-established diagnostic infrastructures with a high volume of testing, driving consistent demand. The presence of a large number of accredited laboratories and a strong focus on standardization across the region supports market growth. However, market dynamics vary between Western and Eastern Europe, with the latter showing potential for growth as healthcare systems modernize.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for IVD quality controls, driven by rapidly improving healthcare infrastructure, increasing healthcare expenditure, and a growing middle class. Countries such as China, Japan, and India are key contributors. Rising awareness of the importance of diagnostic accuracy, government initiatives to improve healthcare quality, and the expanding base of clinical laboratories are major growth drivers. The region also benefits from increasing local manufacturing of IVD products and quality controls, making them more accessible. The high burden of infectious and chronic diseases further propels the demand for reliable diagnostic testing and associated quality assurance.
South America
The South American IVD quality control market is experiencing steady growth, though it is less mature compared to North America and Europe. Brazil is the largest market in the region, aided by a large population and a developing universal healthcare system. Increasing government focus on improving laboratory standards and the gradual expansion of private healthcare are key factors. Economic volatility in some countries can impact market growth, but the essential nature of quality controls for accurate diagnostics provides a stable baseline demand. The market is characterized by a growing adoption of automated analyzers, which in turn increases the need for corresponding quality control products.
Middle East & Africa
The Middle East & Africa region shows diverse market dynamics. The GCC countries, particularly Saudi Arabia and the UAE, have well-funded healthcare systems and are adopting advanced diagnostic technologies, creating a demand for sophisticated quality controls. In contrast, many parts of Africa face challenges related to healthcare infrastructure and funding. However, there is a growing recognition of the importance of laboratory quality management to combat infectious diseases and improve public health outcomes. International aid and initiatives aimed at strengthening laboratory capacity in Africa are expected to gradually drive the adoption of basic to intermediate quality control processes in the region.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global in vitro diagnostics quality control market was valued at USD 0.57 billion in 2024 and is expected to reach USD 0.72 billion by 2032.
-> Key players include Bio-Rad Laboratories, Inc., Siemens Healthineers AG, Abbott Laboratories, and Roche, among others.
-> The market is projected to grow at a compound annual growth rate (CAGR) of 3.4% during 2025-2032.
-> Key applications include hospitals, clinical laboratories, and research institutes.
-> Growth is driven by increasing diagnostic testing volumes and demand for reliable results.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates